Search Hotels in San Anselmo

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024

January 23, 2024

January 23, 2024 -- California's Court of Appeals denies Gilead Sciences' request for immunity from liability

Courts Find Gilead "Morally Blameworthy" for Withholding HIV Medication

January 23, 2024

Via 24-7 Press Release

Gilead Provides Update on Phase 3 EVOKE-01 Study

January 22, 2024

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

3 health care stocks off to strong starts in 2024

January 10, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Topics Artificial Intelligence

Exposures Artificial Intelligence

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

Topics ETFs

Gilead Sciences to Present at Upcoming Investor Conference

December 21, 2023

U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

December 21, 2023

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

December 19, 2023

Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

December 11, 2023

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

December 11, 2023

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

December 11, 2023

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

December 11, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

Topics ETFs

December 07, 2023

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

November 30, 2023

J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown

J&J, Gilead, BMS: A look at undervalued dividend payers

November 29, 2023

Kite and Arcellx Announce Expansion in Strategic Partnership

November 15, 2023

Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance

November 09, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Buying the dip in high-yield Gilead Sciences

November 09, 2023

Pharma stock Gilead Sciences is well-positioned for the next few years with a growing core business, a healthy pipeline, and cash flow to sustain capital return

Exposures COVID-19

Gilead Sciences to Present at Upcoming Investor Conferences

November 08, 2023

Gilead Sciences Announces Third Quarter 2023 Financial Results

November 07, 2023

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

November 06, 2023

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

November 03, 2023

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

November 02, 2023

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

October 31, 2023

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

October 24, 2023

New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

October 20, 2023

Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities

October 19, 2023

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

October 18, 2023